Cargando…

Clinical characteristics of 9 cancer patients with SARS-CoV-2 infection

In December 2019, a cluster of pneumonia cases was caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China. Cancer patients are a special group, the immunity of them will be suppressed because of various anti-tumor treatments, and the risk of infection will be grea...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Yong, Zhang, Bo, Zhang, Xufeng, Yi, Cunjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224342/
https://www.ncbi.nlm.nih.gov/pubmed/32435272
http://dx.doi.org/10.1186/s13020-020-00328-8
_version_ 1783533882394542080
author Zeng, Yong
Zhang, Bo
Zhang, Xufeng
Yi, Cunjian
author_facet Zeng, Yong
Zhang, Bo
Zhang, Xufeng
Yi, Cunjian
author_sort Zeng, Yong
collection PubMed
description In December 2019, a cluster of pneumonia cases was caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China. Cancer patients are a special group, the immunity of them will be suppressed because of various anti-tumor treatments, and the risk of infection will be greatly increased, so we will report clinical features of 9 cancer patients with SARS-CoV-2 infection. 5 (56%) patients were ordinary type, 3 (33%) were severe type, and 1 (11%) was critical type. A total of 8 patients received combined therapy of traditional Chinese medicines and western medicines. From the clinical outcomes of these 8 patients, western combined therapy of traditional Chinese medicine was indeed an effective treatment method. D-dimmer rise, infection index rise, and chest CT(computed tomography) progression may be clinical warning indicators for severe patients, in our study, more 50% of patients had elevated levels of these indicators, but only 44% (including the dead) of patients had received treatment in the intensive care unit. 5 (56%) ordinary type patients had been discharged, while the 1 (11%) critical type patient died 3 days after admission. Cancer comorbidity seems to have no direct relationship with severe events, and the combination of traditional Chinese medicine and western medicine may be effective in the prevention and treatment of novel coronavirus-infected pneumonia (NICP).
format Online
Article
Text
id pubmed-7224342
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72243422020-05-15 Clinical characteristics of 9 cancer patients with SARS-CoV-2 infection Zeng, Yong Zhang, Bo Zhang, Xufeng Yi, Cunjian Chin Med Commentary In December 2019, a cluster of pneumonia cases was caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China. Cancer patients are a special group, the immunity of them will be suppressed because of various anti-tumor treatments, and the risk of infection will be greatly increased, so we will report clinical features of 9 cancer patients with SARS-CoV-2 infection. 5 (56%) patients were ordinary type, 3 (33%) were severe type, and 1 (11%) was critical type. A total of 8 patients received combined therapy of traditional Chinese medicines and western medicines. From the clinical outcomes of these 8 patients, western combined therapy of traditional Chinese medicine was indeed an effective treatment method. D-dimmer rise, infection index rise, and chest CT(computed tomography) progression may be clinical warning indicators for severe patients, in our study, more 50% of patients had elevated levels of these indicators, but only 44% (including the dead) of patients had received treatment in the intensive care unit. 5 (56%) ordinary type patients had been discharged, while the 1 (11%) critical type patient died 3 days after admission. Cancer comorbidity seems to have no direct relationship with severe events, and the combination of traditional Chinese medicine and western medicine may be effective in the prevention and treatment of novel coronavirus-infected pneumonia (NICP). BioMed Central 2020-05-14 /pmc/articles/PMC7224342/ /pubmed/32435272 http://dx.doi.org/10.1186/s13020-020-00328-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Commentary
Zeng, Yong
Zhang, Bo
Zhang, Xufeng
Yi, Cunjian
Clinical characteristics of 9 cancer patients with SARS-CoV-2 infection
title Clinical characteristics of 9 cancer patients with SARS-CoV-2 infection
title_full Clinical characteristics of 9 cancer patients with SARS-CoV-2 infection
title_fullStr Clinical characteristics of 9 cancer patients with SARS-CoV-2 infection
title_full_unstemmed Clinical characteristics of 9 cancer patients with SARS-CoV-2 infection
title_short Clinical characteristics of 9 cancer patients with SARS-CoV-2 infection
title_sort clinical characteristics of 9 cancer patients with sars-cov-2 infection
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224342/
https://www.ncbi.nlm.nih.gov/pubmed/32435272
http://dx.doi.org/10.1186/s13020-020-00328-8
work_keys_str_mv AT zengyong clinicalcharacteristicsof9cancerpatientswithsarscov2infection
AT zhangbo clinicalcharacteristicsof9cancerpatientswithsarscov2infection
AT zhangxufeng clinicalcharacteristicsof9cancerpatientswithsarscov2infection
AT yicunjian clinicalcharacteristicsof9cancerpatientswithsarscov2infection